Should I mention a mutual connection in a cold email?

Only if the connection would be comfortable with it. Name-dropping someone who barely knows you can backfire. If you do mention them, say exactly how you know them in one clause and move on. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Should I include a recording in the demo follow-up?

If you recorded it and they agreed, yes, plus timestamps for the two parts they cared about. A raw 40-minute link with no map is homework. Add the three bullets they'd need to brief a colleague. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it okay to send this cold email on LinkedIn instead of email?

Yes if this CEO is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals cold email?

Don't use consumer-startup slang. It's a credibility leak. A long origin story or a request to 'pick your brain.' Don't send a 19-page deck that relitigates features they skipped. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Can I use aggressive sales language in pharma outreach?

No. Unapproved claims, off-label hints, and fake urgency can create real problems. Be operational: timelines, review status, access, meeting logistics. Save clinical discussion for approved materials and the right role. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Pharmaceuticals · CEO · After Demo

Cold Email Template for Pharmaceuticals CEO: After Demo

Use this cold email template when you're emailing a CEO in Pharmaceuticals (after a demo). They saw the product. Now they're comparing, forwarding, or quietly deciding it wasn't for them. Keep the note aligned with Direct, adult, light on process jargon. Talk like a peer who did the homework.

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this cold email work for a Pharmaceuticals CEO?

Give them permission to say you're early.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CEO actually reads: Keep the whole note under 70 words unless they asked for detail.
Replay the two moments they leaned in, and the one concern they named.
Make the first ask smaller than a 30-minute call.

When should I send this to a Pharmaceuticals CEO?

Don't follow a cold email the next morning. Give it 4 business days. Same day with the recap. A value bump 3 days later if they went quiet. For this combo, treat "Same day, then 3 days if silent" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CEO, Keep the whole note under 70 words unless they asked for detail.

What this CEO actually cares about

A CEO in Pharmaceuticals is protecting time, reputation, and optionality. They skim on a phone between meetings. If the first two lines don't name a business outcome, the rest never gets read. The hook that earns a look is a P&L, risk, or competitive issue they already feel. The ask should stay at this size: one decision or a 10-minute yes, not a workshop. Delete trigger: A long origin story or a request to 'pick your brain.' a P&L, risk, or competitive issue they already feel a P&L, risk, or competitive issue they already feel

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Proof that lands: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone direct, adult, light on process jargon.
Research one real trigger. Fake personalization is worse than none.
Time it for Same day, then 3 days if silent. Same day with the recap. A value bump 3 days later if they went quiet.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this after demo note?

Opening with your company story is how cold email dies.
Don't send a 19-page deck that relitigates features they skipped.
Don't use consumer-startup slang. It's a credibility leak.
A long origin story or a request to 'pick your brain.'

How does this after demo scenario compare?

Dimension	For this template
Best send window	Same day, then 3 days if silent
Ideal length	Keep the whole note under 70 words unless they asked for detail.
Primary ask	one decision or a 10-minute yes, not a workshop
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Direct, adult, light on process jargon. Talk like a peer who did the homework.
Unlike after meeting	They have product context now. Speak to what they saw, not to a generic intro.
Unlike after proposal	Pricing may not be on paper yet. Don't jump to 'ready to sign.'

What should I copy and send?

Copy-ready template

Subject

Idea for [Company Name]'s [pain]

Body

Hi [First Name],

Saw [trigger] and figured this might be on your plate.

I'm writing because a label update, a launch window, or a congress. Teams like [peer example] use [Your Product] to cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft in [timeframe]. The fit depends on whether follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick is actually costing you time through MLR.

Given this is after a demo, ask who else needs to see it, or whether a narrower use case is the better start.

Wrong person? Point me to whoever owns [pain].

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Don't follow a cold email the next morning. Give it 4 business days. Same day with the recap. A value bump 3 days later if they went quiet. After that, send a breakup note and archive it. A CEO who wants it will answer a clean close more often than a fifth bump.

Related templates

Want a custom draft instead? Try the email generator.